NextBio and Sanofi are teaming up to incorporate omics and clinical data into the latter firm’s drug R&D program, Translational Medicine for Patients. Through this partnership, NextBio will provide Sanofi’s clinical trials and hospital platforms with its platform, which enables users to aggregate and interpret large quantitities of molecular and other life sciences data, allowing them to access and utilize patient data in real time. Financial terms of the agreement were not disclosed.
“Sanofi has long used NextBio as an important component of the company’s preclinical research programs,” Saeid Akhtari, NextBio president and CEO, said in a statement. “The new translational medicine partnership with NextBio, with its Big Data Genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes.”